RogerMLyonsMDF.A.C.P.

Hematology • San Antonio, TX

President Cancer Care Centers of South Texas

Join to view full profile

Dr. Lyons is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lyons' full profile

Already have an account?

Office
5206 Research Dr
San Antonio, TX 78240
Phone+1 210-595-5300

Fax+1 210-614-8740

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 1972 - 1975
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1971 - 1972
University of ManitobaClass of 1967

Certifications & Licensure

TX State Medical License 1975 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2004-2014
Top Doctors:SE Texas Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma Start of enrollment: 2009 Nov 01
Terminated
Phase 2
Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia Start of enrollment: 2009 Apr 01
Terminated
Phase 2
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2009 Nov 01
Completed
Phase 1
Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) Start of enrollment: 2010 Jun 01
Completed
Phase 2
Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts Start of enrollment: 2010 Nov 01
Completed
Phase 3
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant Start of enrollment: 2011 Apr 20
Completed
Phase 3
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA Start of enrollment: 2013 Dec 01
Completed
Phase 2
A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders Start of enrollment: 2014 May 01
Completed
Phase 2
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients Start of enrollment: 2014 Mar 08
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

1456 citations
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta
The New England Journal of Medicine. 2012-03-01
291 citations
Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period.
Steven R. Deitcher, Craig M. Kessler, Geno J. Merli, James R. Rigas, Roger M. Lyons
Clinical and Applied Thrombosis/hemostasis. 2006-10-01
77 citations
Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes
Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Jesus G. Berdeja, Yasmin Abaza, Elias J. Jabbour
Cancer. 2017-03-15

Abstracts/Posters

Disease and Clinical Characteristics of Patients with Myelofibrosis Enrolled in the MOST Study
Roger M. Lyons, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with N...
Roger M. Lyons, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazo...
Roger M. Lyons, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

RogerMLyonsMDF.A.C.P.

Dr. Lyons is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Viewing the full profile is available to verified healthcare professionals only.